Foamix rockets on rosacea data

Foamix Pharmaceuticals (Nasdaq: FOMX) was up by 20% in pre-market trading on Wednesday after releasing results from Phase III studies of FMX103 1.5% minocycline foam.

The Israeli-headquartered skincare specialist announced that the two trials, which were investigating FMX103 in moderate-to-severe papulopustular rosacea, met their primary endpoints.

Linda Stein Gold, a dermatologist at Henry Ford Health System, principal investigator in one of the studies and advisor to Foamix, said: “These results are impressive, with treatment success being achieved in a high proportion – approximately 50% – of patients as well as clinically-meaningful reductions in inflammatory lesions.”